Introduction: Colorectal cancer (CRC) is one of the commonest types of cancer that affects a significant proportion of the population and is a major contributor to cancer related mortality. The relatively poor survival rate of CRC could be improved through the identification of clinically useful biomarkers.
Introduction

Colorectal cancer background
Colorectal cancer (CRC) is one of the commonest types of cancer and a major cause of cancer related death [1] . The survival rate is still relatively poor particularly for patients presenting with distant metastases [2] . Established primary CRC can generally be diagnosed based on the histopathological characteristics of tissue biopsies obtained at colonoscopy [3] .
However, it can be more difficult to diagnose early CRC or CRC that presents as metastatic disease [4, 5] . Screening programmes for CRC using either colonoscopy or faecal occult blood testing have shown that they may reduce the mortality rate from CRC [6, 7] .
Nevertheless, current screening methods suffer from several drawbacks including lack of sensitivity and poor participation rates that impede their potential benefits [8] .
Prognosis using the current staging system which is based on the histopathological examination of resected CRC does not necessarily reflect the biological heterogeneity of CRC and thus patients with the same tumour stage often have variation in clinical outcome [9] . This staging system is also the main method whereby therapeutic options are determined, yet patients with the same stage often respond differently to the same treatment [10, 11] . Therefore, reliable and easily measurable biomarkers are urgently required to assist clinicians to overcome current difficulties in clinical practice (Figure 1 ).
Proteomics and genomics perspective on biomarker discoveries
A biomarker is defined as a "characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention" [12] . In recent years, there have been a noticeable shift in the biomarker literature towards genomics and transcriptomics technologies, which 4 dysplasia and greater "villousness" [28] . Patient management guidelines (e.g. time interval between surveillance colonoscopies) are based on the identification of these histopathological characteristics [29] . Since only less than 5% of polyps proceed to malignancy, it is imperative to identify novel protein biomarkers to further assist in identifying high-risk adenomas and therefore allow rational use of endoscopic resources [5] . Proteomic studies have identified several candidates proteins associated with the malignant transformation of adenomatous polyps (Table 1) .
Kininogen-1 was identified as a marker for the diagnosis and/or screening of the malignant transformation of adenomas [30] . This study analysed the serum samples of 110 participants using matrix assisted laser desorption ionization time-of-flight (MALDI-TOF/TOF-MS). Kinongen-1 levels were significantly lower in normal mucosa compared with CRC and advanced colorectal adenoma, which is consistent with a previous finding [36] . Nevertheless, the exact role of kininogen-1 in CRC pathogenesis remains unclear.
Moreover, it is not clear whether the protein levels vary between different types of adenomas.
Therefore, there is a need for further experimental validation of the results especially in the presence of contradictory results regarding the levels of kininogen-1 detected in adenoma and carcinoma [37] .
In another study, the analysis of plasma samples using MALDI-TOF/TOF-MS has enabled the identification of a peptide signature to monitor and predict the malignant transformation of polyps in familial adenomatous polyposis (FAP) [31] . This study was the first to show that peptide profiling can be used to monitor CRC development in FAP patients.
However, a significant concern is the specificity of the peptide signature for CRC because some of the identified peptides are derived from proteins (e.g. complement C3 and C4) involved in inflammation. Moreover, enzyme linked immunosorbent assay (ELISA) validation of complement proteins revealed contradictory results to the proteomic findings. This highlights the need for further evaluation of the results in an independent and much larger cohort since the ELISA was performed only on a small cohort (10 FAP, 8 adenoma, and 36 CRC). The contradictory ELISA results were attributed to the increased activity of proteases rather than the circulating level of precursor proteins. The inability to use ELISA for assessing and monitoring the peptide signature makes it much more difficult to validate the findings and may compromise the potential clinical utility of this proposed biomarker signature. For the detection of peptides using ELISA, it may be possible to use monoclonal antibodies produced against short synthetic peptides [38] .
A diagnostic portfolio of proteins that could be used to distinguish adenomas from CRC or healthy controls was identified using MALDI-TOF/TOF-MS [32] . This research investigated plasma samples from healthy controls, and from patients with colorectal adenomas or invasive disease. Blood-based biomarkers which can accurately diagnose potentially malignant adenomas could have great clinical utility. However, the proteins identified in this study included inflammatory cytokines [39] . Moreover, the validation was only conducted on a small cohort (30 adenomas and 30 carcinomas). Hence, additional studies are required before these proteins can be considered as potential diagnostic markers.
Proteomic technologies can also be utilised to assess urine for the purpose of identifying biomarkers associated with high-risk adenomas [33] . This study has found that urinary levels of prostaglandin metabolites (PGE-M) measured using liquid chromatographymass spectrometry (LC/MS) are associated with high-risk adenomas. The study cohort contained a relatively large number of controls and adenomas that were from a prospective cohort. There are limitations in the design and the composition of the cohort used in this study. Firstly, the cohort only included females. Secondly, and more importantly, there were no colorectal carcinomas in the samples analysed. Nevertheless, the findings are consistent with other proteomics studies that have measured urinary PGE-M using the same method [40, 6 41]. The study by Shrubsole and colleagues [40] used 224 cases with at least one advanced adenoma, 152 small tubular adenomas, 300 single small tubular adenoma, and 364 controls.
Whereas the study by Johnson et al. [41] assessed PGE-M in 58 CRC, 70 polyps, 28 Crohn's disease, and 72 healthy controls. In addition, Nakanishi et al. [42] found that the inhibition of PGE2 production suppresses intestinal carcinogenesis in an APC-mutant mouse model. A significant concern is that PGE-M are also involved in several inflammatory pathways and also other malignancies, hence there is a need to assess the specificity of urinary PGE-M in CRC versus other cancers and inflammatory diseases (e.g. Crohn's disease, ulcerative colitis) [43] . It is therefore difficult to interpret the association between PGE-M levels and development of CRC without further study of well-defined cohorts.
In another study, nuclear magnetic resonance (NMR) spectrum analysis of urinary samples of 988 high-risk individuals who required colonoscopy identified metabolomics signatures associated with CRC [34] . Using an algorithmic classifier of metabolic signature (4 metabolites and 4 clinical questions), the study showed it was possible to predict individuals who required colonoscopy with an accuracy better than faecal occult blood test. This is potentially a useful addition to the clinical practice because it could ensure patients avoid colonoscopy. Additionally, the learning algorithmic classifier may represent a novel method of transforming complex proteomics data into clinically relevant parameters.
However, the study classified both participants with hyperplastic polyps or adenomas into one group requiring colonoscopic follow-up even though the risk of progression to CRC significantly differs between the two groups. The risk of malignant transformation should be the main determinant of who needs colonoscopy. Furthermore, it is difficult to interpret these findings without further study since only two carcinomas were included in the study. The lack of early CRC from the samples may results in a failure to identify important changes in proteins associated with the early stages of malignant transformation. 
Diagnosis of metastatic CRC
The identification of the primary origin of an unknown metastatic tumour is still challenging in spite of the availability of a variety of diagnostic methods including histopathology, molecular analysis, imaging, and endoscopy [4] . The majority of cancers of unknown primary are metastatic adenocarcinomas of which around 7 % are of colo-rectal origin [44] . Failure to identify the primary origin of a tumour is a significant problem since the clinical management of patients particularly the selection of appropriate treatment regimens depends on the identification of the specific cancer type. Histopathological assessment using a combination of the immunohistochemical markers cytokeratin 20, cytokeratin 7 and CDX2 is often used to identify CRC, although the typical cytokeratin 20+/CDX2+/cytokeratin 7-ve phenotype is not expressed by all colorectal carcinomas [45] .
Recent studies have shown that the assessment of a combination of Stabilin-2 (STAB2) with cytokeratin 7 and cytokeratin 20 can provide a highly sensitive and specific test for CRC diagnosis [46, 47] . Both studies used immunohistochemistry (IHC) to evaluate STAB2, cytokeratin 20 and cytokeratin 7 expression in large cohorts (n = 840 and n = 2696) which included CRC, benign tumours, normal tissues, and other common malignancies. While few studies have focused on the identification of new markers that help differentiate metastatic CRC from other malignancies there is a clear requirement for such biomarkers.
Biomarkers for CRC prognosis
The need for prognostic markers in the clinical practice
A prognostic biomarker can be defined as a (biological) variable that provides prospective information on patient outcome which is complementary to the data obtained by 8 the pathologist from histopathology and on which therapeutic decisions can be guided [48] .
There is unjustifiable scepticism towards prognostic marker studies as they are generally perceived as unnecessary in CRC since histopathological examination of the resected colorectal cancers provide key prognostic information (tumour stage, lymph node stage, extramural venous invasion). However, the clinical outcome can vary considerably between patients who are diagnosed with the same tumour stage especially for patients with stage II and III CRC [3] . Thus, the identification of protein biomarkers on both biopsies of CRC and surgically resected CRC, which reflect the heterogeneity of CRC, will help in providing accurate prediction of the clinical outcome of patients.
Recent proteomics discoveries
Large numbers of potential prognostic markers have been identified using proteomicbased approaches (supplementary information Table S1 ). For example, a combination of Nano LC-MS and gene expression analysis of stage IV CRC patients (n = 46) was used to identify metastasis associated markers [49] . Maspin was found to vary between the two groups of patients divided based on time to recurrence (Table S1 ). Immunohistochemical analysis of maspin expression in a tissue microarray containing 419 stage II and III CRC samples indicated it was an independent prognostic factor of time to recurrence and disease specific survival in stage III CRC. The finding was validated using three transcriptomics data sets (75 stage II, 78 stage III, and 53 stage IV). Consistent with this study, high maspin expression was linked to increased apoptosis resistance in a colon cancer cell line (HCT-116RC) [50] . The discovery of maspin highlights the fact that some proteins might have a stage-specific function and thus have stage-related expression profiles that could be detected through proteomics. Stage-specific markers carry important prognostic information that 9 could complement or even replace the current staging system when surgical specimens are not available. Several other studies have demonstrated that it is possible to identify protein markers associated with tumour stage using comparative proteomics (studies 1, 2, and 9 described in Table S1 ). However, it is worth noting that the size of the samples used in those studies were small and therefore further validation using larger and independent cohorts is required.
Stomatin-like 2 (STOML2) protein was identified using high-performance LC-MS analysis of membrane proteome in 28 pairs of normal and CRC tissues [51] . The subsequent assessment of the protein expression by IHC showed a strong association between STOML2 and disease-specific survival. High expression of STOML2 was associated with decreased CRC-related survival. Furthermore, the plasma levels of STOML2 as measured by ELISA were higher in early stage CRC compared with healthy individuals, which suggest STOML2 could potentially be used as a screening marker. The main drawback of this study is the small numbers of CRC samples included in the proteomics analysis (n = 28), ELISA (n = 70) and IHC (n = 205). Additional validation using a large and independent cohort is still needed as well as further investigation of the role of STOML2 in CRC pathogenesis.
Another interesting study has revealed a prognostic protein signature using tailored computational analysis of proteomics data generated via a combination of LC-MS and targeted LC-MS (SRM) assessment of plasma samples [52] . The protein signature (major histocompatibility complex class I-A, complement factor H, CD44, protein tyrosine phosphatase, receptor type J, haptoglobin, and cadherin 5 type 2) was associated with different prognostic parameters and could stratify patients to distinct prognostic subgroups.
The study also used data from three external transcriptomics cohorts for additional validation.
The findings of this study are encouraging and may have considerable implication on the management of CRC patients because, unlike the key pathological prognostic factors which require examination of a resected CRC specimen, this protein signature can be evaluated noninvasively in the plasma. Nevertheless, additional assessment of the findings on a larger cohort is needed because only 202 CRC samples were used. Moreover, there may be a need to evaluate whether this protein signature is detectable by ELISA since this technology is generally easily implemented in laboratories where quality assurances and best practice guidelines are in place. Other studies which have also utilised proteomics analysis of plasma for prognostic marker identification are described in Table S1 .
The analysis of preclinical models (cell lines and xenograft tumours) using 2-D difference gel electrophoresis (DIGE) and MALDI-TOF/TOF MS followed by validation with human samples provides another approach to the identification of prognostic markers [53] . Comparative proteome analysis found stathmin 1 (STMN1) levels to be lower in colon cancer cell line (HCT-116) compared to its metastatic derivative E1. Both knockdown and overexpression of STMN1 in HCT-116 and E1 showed it was associated with significant changes in cell migration, invasion, adhesion, and colony formation. This study also performed IHC staining on a tissue microarray containing 324 primary CRC. The expression of STMN1 was higher in CRC compared to the adjacent normal mucosa, and increasing intensity of expression was associated with poorer CRC specific survival. These results are consistent with a recent study which showed that the silencing of STMN1 inhibited metastasis in (E1) and (HCT116) colon cancer cell lines [54] . However, in contrast to the finding of that study, the expression of STMN1 assessed by IHC using 546 CRC cases from two independent cohorts showed that the overexpression of STMN1 was associated with improved survival [55] . Therefore, although STMN1 has shown a promising potential as a prognostic marker for CRC, there is a need for further research of STMN1 in CRC.
Although some studies have used large and well-characterised cohorts for the validation of their proteomics results [56, 57] , the majority of studies have used relatively 11 small cohorts. Another limitation is the insufficient reporting in a variety of aspects including the collection and processing procedure of specimens, inclusion criteria of patients, clinicopathological characteristics of the cohort and clearly defined endpoints. Many biomarker studies still suffer from lack of adherence to the Reporting Recommendations for Tumour Marker (REMARK) guidelines [58] . Compliance with the REMARK guidelines should help to standardise and improve the quality of biomarker studies [59] .
Biomarkers for predicting the outcome of CRC therapy
The need for predictive markers in the clinical practice
A predictive biomarker is defined as a variable that indicates the outcome of a specific type of therapy and therefore aids in making treatment decisions [60] . Predictive markers are needed in CRC management because the benefit of neoadjuvant and/or adjuvant therapy is not clear for a significant proportion of patients [10, 11] . The increasing range of therapeutic options have further highlighted the need for predictive biomarkers. One of the few predictive markers to be in current clinical practice is the identification of KRAS mutations as KRAS mutant tumours do not respond to anti-epidermal growth factor receptor drugs [61] .
In addition, the assessment of mismatch repair proteins seems to offer valuable information on the potential benefit of fluorouracil based adjuvant therapy and immune checkpoint inhibitors [62, 63] .
Recent proteomics studies
Several research groups have used proteomics analysis to identify putative predictive markers for CRC (Table 2) . Using a combination of 2D-DIGE and LC-MS/MS to assess serum samples from a group of patients with CRC who had received chemotherapy and bevacizumab, sixty-four differentially expressed proteins were identified between responders and non-responders [64] . The study also used ELISA and IHC to validate three proteins (apolipoprotein E, angiotensinogen and vitamin D binding protein) which were significantly associated with overall survival and or progression free survival in metastatic CRC patients treated with chemotherapy and bevacizumab. This could be useful as less than 50% of patients showed a response to this therapy [69] . Nevertheless, the number of CRC samples in the validation cohort was relatively small (ELISA: n = 68 and IHC: n = 95), therefore further validation of the results is still required.
A panel of 32 proteins associated with CRC was identified using isobaric tags for relative and absolute quantitation (iTRAQ -LC-MS) analysis of cancer-associated fibroblasts obtained from colon cancer and normal tissue [65] . This study presented strong and welldesigned discovery model whereby proteins derived from colon-associated fibroblast can be assessed for biomarker discoveries. High expression of lysyl oxidase-like 2 (LOXL2) was associated with poor overall survival and high recurrence, and demonstrated predictive value for adjuvant therapy in stage II colon cancer. The results were validated on a number of independent cohorts using different methods (IHC, gene expression profiling and polymerase chain reaction (PCR)). Still, the number of colon cancer cases in the validation cohorts (IHC: n = 121 and PCR: n= 70) was relatively small and hence further validation is required. A previous study found LOX, a family member and paralog of LOXL2, to play an important role in promoting CRC angiogenesis using in in vitro (SW480 and SW620 cell lines) and mouse models (LS174T human CRC cell lines grown as subcutaneous tumours in nude mice) [70] . The results of the preclinical models were further validated by IHC (on a CRC tissues microarray (n=515)) which showed the expression of LOX correlated with VEGF expression and blood vessel formation in patients [70] . 13 Dasatinib, an inhibitor of Src tyrosine kinases, is currently being evaluated for use in CRC. However, this therapy is expensive and can cause side effects. Therefore, there is a need for predictive biomarkers that can accurately select patients based on the potential response to this drug. In a recent study, delta-type protein kinase C (PKCδ) was identified as predictive marker for dasatinib in CRC [67] . Shotgun phosphotyrosine proteomics was used to obtain a global view of tyrosine phosphorylation in HCT-116 colon cancer cell lines and HCT-116 xenograft tumour. The results showed that the measurement of PKCδ pY313 as a promising method for assessing the response to dasatinib. However, there is still an apparent lack of research focused on the identification of predictive markers. This can be attributed in part to the lack of readily available, large, wellcharacterised cohorts.
Biomarkers for CRC screening
The need for screening markers in clinical practice
The five-year survival rate of CRC patients is significantly worse for those patients diagnosed with metastatic disease compared with early stage disease [1] . Considering CRC is often asymptomatic at early stages of development, sensitive screening methods may reduce CRC associated mortality through early diagnosis when treatment is more effective.
Flexible sigmoidoscopy and faecal occult blood test based screening programmes have shown some success in reducing the mortality rate of CRC [6, 7] . However, faecal occult blood tests generally suffer from a lack of sensitivity and a significant false positive rate, while endoscopic examination of the colon is invasive, expensive and involves a degree of risk [8] . Therefore, there is a need for accurate, cost effective, reliable, and non-invasive The plasma levels of adiponectin measured using ELISA seem to be inversely associated with CRC risk in men in a large prospective cohort (n=616 CRC and n=1205 controls) [71] . Further validation studies are needed before adiponectin can be used as screening marker. MicroRNAs, cell-free DNA and circulating tumour cells are available in the peripheral blood and they have shown encouraging results as useful screening markers for CRC, however further optimisation is still required [3, 72] .
Recent proteomics studies
Proteomics studies enabled the identification of large number of proteins that may potentially be used as screening biomarkers for CRC (supplementary material Table S2 ).
The use of a multiple autoantibody-based assay as a screening tool for CRC has shown promising results [73, 74] . In a recent study, 64 autoantibodies were assessed using multiplex serology assay, and a panel of four autoantibodies showed combined strong diagnostic ability in detecting early CRC [75] . The study conducted following a robust approach using technology that allows simultaneous assessment of a large number of potential markers in blood samples selected from the target screening population.
Nonetheless, the relatively small cohort used in validation (49 CRC, 29 non-advanced adenoma, and 99 advanced adenoma) and the dissimilarities in the clinico-pathological characteristics between cohorts used for training and validation are limitations which could influence the outcome of this study. Moreover, there are concerns regarding the determination of the appropriate cut-off values.
A panel of proteins including APC-binding protein EB1 (MAPRE1) were elevated in CRC compared to healthy controls in a study that used LC-MS analysis of plasma samples 15 and CRC cell lines [76] . The study used one cohort (90 CRC) for discovery phase and two independent cohorts for ELISA validation. The samples were collected 17 months prior to CRC diagnosis in the discovery cohort, 7 months prior to diagnosis in one validation cohort and from newly diagnosed patients in the second validation cohort. The inclusion of priordiagnosis samples can help in detecting important protein changes that happen very early in the process of CRC development. However, one validation cohort included only 32 CRC (with only four stage I cases) and the second cohort included 58 CRC without providing further characteristics of the samples. Furthermore, the study used two cohorts that consisted entirely of women while the third cohort was composed of both women and men. Therefore, further assessment of the results with a large cohort in a well-designed study is imperative.
In another study, the diagnostic potential of MAPRE1 in CRC was assessed using a combination of LC-MS and antibody array analysis of plasma samples, followed by IHC validation on fixed tissue samples [77] . The level of MARPE1 was higher in adenoma and CRC compared to normal healthy samples, which is consistent with the previous study [76] .
In this study, the combination of MAPRE1 with carcinoembryonic antigen and adenylate kinase 1 has shown promising results in differentiating adenoma and early CRC, respectively, from healthy controls. Nevertheless, the relatively small number of samples (antibody array: 60 adenomas and 60 CRC/ IHC: 10 adenomas and 66 CRC) makes it difficult to determine the clinical usefulness of this marker combination. MAPRE1 knockdown in APC mutant (HT-29) and APC wildtype (HCT-116) showed an anti-proliferative effect which maybe dependent on APC status [78] . This indicates the importance of further research of the role of MAPRE1 in CRC and the need for further validation.
A diagnostic protein signature (ceruloplasmin, serum paraoxonase/arylesterase 1, serpin peptidase inhibitor, clade A, leucine-rich alpha-2-glycoprotein, and tissue inhibitor of metalloproteinases 1) was identified using proteomics and computational analysis [79] . The is a need for further validation using larger cohorts and it may be necessary to investigate the finding using alternative technique such as ELISA.
Proteomics analysis of blood proteome is not the only approach exploited to identify screening markers. Other studies have shown promising results using proteomics to assess urine, faecal, tissues and cell lines (Table S2) . Follow up validation is required in larger cohorts for all these biomarkers.
The role of proteomics in molecular pathological epidemiology (MPE)
The rise in the incidence of CRC in developed countries have been linked to classic epidemiological factors such as diet, physical exercise, smoking, alcohol intake and an ageing population and these factors can be associated with specific molecular abnormalities [80] .
Such epidemiological factors can be integrated by MPE to provide a more comprehensive understanding of CRC [81] . The phenotype of a disease can be better defined within the paradigm of MPE, which interpret specific molecular signatures within the context of recognised aetiological factors [82, 83] . For example, both CpG island methylator phenotype and microsatellite status in CRC can be linked to a variety of aetiological factors [84, 85] .
Therefore, proteomics can provide another dimension for MPE. The challenges, opportunities, and recommendations of this multidisciplinary approach have been recently discussed at the second international MPE meeting [86] .
Progress and difficulties
Potentially significant limitations observed in many of proteomics studies are the sample size, annotation and the composition of the cohorts. For example, there is a lack of early stage CRC in samples used for investigating potential screening markers. The presence of advanced CRC instead may distort the findings because changes in the profile of plasma proteome are likely to be greater than in early invasive lesions. Moreover, there is a lack of detailed clinicopathological characteristics of many cohorts (e.g., tumour differentiation, presence of extramural venous invasion, stage).
Another potential problem is the low levels of individual protein markers in early tumours which might not be reliably detected in serum with current technologies since it can be difficult to detect low abundance proteins especially in complex protein mixtures [87] .
New strategies such as enrichment technologies (e.g. enrich for N-or C-terminal peptides), labelling approaches (e.g. neutron encoding (NeuCode)) may help overcome the inconsistency and lack of sensitivity of unlabelled MS, particularly when dealing with posttranslation modifications [88] . Targeted MS is also gaining popularity because it is highly specific, accurate, and even applicable when there are problems with the antibodies [89] .
However, there are difficulties when targeting several biomarkers simultaneously in multiple samples, and the method requires exhaustive and challenging optimisation process. Some of the challenges might potentially be addressed using a wider MS/MS window termed Sequential Window Acquisition of all THeoretical Mass Spectra (SWATH) strategy [90] .
Finally, new approaches that are increasingly used include immunocapture strategies such as reverse phase protein microarray and immunocapture coupled to mass spectrometry [91] .
Some of the advantages using such methods include the ability to measure multiple targets with highly sensitivity, requiring only small volume of serum or plasma, and with no need for 18 albumin depletion. However, the main weakness of this method is the dependency on the quality of the antibodies.
Expert commentary
"Precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient" [92] . The ongoing improvements in proteomic technologies should enable a comprehensive profiling of the proteome to provide a platform from which specific biomarkers necessary for precision medicine can be identified. In colorectal cancer there is still an urgent need for sensitive, reliable, and cost-effective biomarkers to complement the current methods of diagnosis, prognosis, therapy determination, and screening. Proteomics studies have generated a large number of potentially useful biomarkers. However, no protein biomarkers appear to have been successfully translated into clinical practice. This is attributed in part to the lack of reproducibility of results and the limitations of the validation studies. The reproducibility of proteomics studies is compromised by deficiencies in the studies design; small sample size, variations in the sample preparation and storage protocols, and complexities of data analysis and interpretation [93] . The lack of standardisation between different laboratories regarding quality assurance in the analytical techniques makes the results difficult to replicate and interpret [94] . The lack of reproducibility of the results could be minimised if the studies adopted strong experimental design and adhered to best practice guidelines. In addition, the introduction of automated quality control might significantly improve the reproducibility of proteomics results [95] .
Lack of follow-up validation studies and deficiencies in validation assays also contribute to the lack of biomarkers success [96] . The assessment of biomarkers studies and their subsequent validation can seriously be hindered by the lack of large collaborative projects, shortage of well-characterised samples, inconsistency of proteomics results, and insufficient reporting. Consequently, it makes it difficult to interpret, analyse, and validate the findings. The characteristics of samples should be carefully selected, justified, and clearly stated because they effect the results of biomarker studies. Finally, the validation methods (often antibody based) also suffer from absence of standardisation, absence of reliable antibodies, lack of best practice and quality controls [97, 98] . Rigorous and standardised characterisation process is needed to validate the antibodies used for immunoassays [99] .
Five-year view
Further advancement in proteomics technologies will result in a more accurate assessment of plasma, serum, tissues, urine, saliva, and faeces proteome. Moreover, the introduction of sophisticated computational software should lead to improved and consistent data generation and analysis. There will also be significant improvement in study design, quality of samples, quality of antibodies, and adherence to best practice guidelines. It is also expected that there will be more collaborative projects with pooling of a wide range of expertise and resources. Thus, more biomarker targets will be identified using proteomics but their potential impact on the clinical practice is largely determined by the amount of progress made in addressing current limitations.
Key issues
• CRC is a common cancer with significant mortality.
• Biomarkers offer a solution to some of the current problems in CRC clinical management.
• Major advancements in proteomics coupled with innovative computational analysis have allowed the analysis of complex protein samples.
• Large numbers of potential CRC biomarkers have already been identified for use in diagnosis, prognosis, therapy determination, and screening.
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• The majority of proteomics studies have focused on prognosis and screening.
• The failure of biomarkers is the consequence of three main factors; lack of validation, limitations in proteomics technologies and methodology deficiencies.
• More biomarkers will be identified considering the ongoing advancement in proteomics strategies and computational analysis.
• Addressing the current limitations will give future biomarkers discoveries a higher chance of success. An overview of colorectal cancer biomarkers types, methods of assessment and potential utilities of biomarkers in clinical practice.
CRC biomarkers
Type Method Potential utilities
• Screening: diagnosis at asymptomatic, early stage and at precancerous stage (high risk population).
• Diagnostic: diagnosis of metastatic CRC of unknown origin and classifications of polyps.
• Prognostic: risk stratification based on natural outcome and guide treatment decisions.
• Predictive: patients stratification based the outcome of particular drug therapy (response and side affect).
• Monitoring: monitor progression and detection of recurrence.
• Others: therapeutic targets and molecular understanding of cancer biology. 
